New data suggests oral fenebrutin effective in relapsing, progressive MS

October 27, 2026
Genentech, released new Phase III data for investigational fenebrutinib in multiple sclerosis, demonstrating reduced markers of chronic brain inflammation as well as more comprehensive disease control versus active comparators. These findings were featured alongside new Ocrevus and Enspryng data.

Fenebrutinib targets progressive biology inside the brain
 

In Brief

  • Fenebrutinib FENtrepid and FENhance 1 and 2 data show a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in MS.
  • Fenebrutinib FENhance 1 and 2 Phase III data show a 55 percent reduction in annualized relapse rate verses active comparator.
 
  • Ocrevus OPERETTA 2 Phase III data show 90 percent of children aged 10–17 remained relapse-free over two years, reinforcing consistent MS control across all ages.
 
  • Enspryng METEOROID Phase III data highlight significant attack reduction and improved functional recovery in MOGAD, an underserved autoimmune disease.
 
   
New data from the FENhance 1 and 2 relapsing MS trials and the FENtrepid primary progressive MS trial support the potential of fenebrutinib as the first and only high-efficacy oral medicine for both forms of MS. 

In the first prospective demonstration of a therapeutic effect on chronic active lesions in MS Phase III clinical trials, data show fenebrutinib reduced the volume of slowly expanding lesions by up to 30 percent in RMS over 96 weeks and PPMS over 120 weeks, along with a 62 percent reduction in accumulation of paramagnetic rim lesions in RMS, versus active comparators. These findings demonstrate that fenebrutinib directly targets chronic neuroinflammation in the brain, a primary driver of disability progression in MS.

In the pooled RMS trials, 75 percent of fenebrutinib-treated patients showed no evidence of disease activity meaning zero relapses, zero MRI activity and zero worsening disability at nearly two years, a 70 percent reduction versus the comparator. These results show fenebrutinib’s potential to suppress disease activity and delay progression.

Pooled RMS data show fenebrutinib reduced the annualized relapse rate by 55 percent versus the comparator over 96 weeks. In addition, fenebrutinib reduced annual total brain volume loss by 23 percent and 12-week composite confirmed disability progression by 16 percent. These findings demonstrate fenebrutinib’s potential to control relapses, to slow brain tissue loss caused by neuronal cell death and to preserve function.  

Ocrevus provides consistent benefits across all age groups

New data show that Ocrevus provides significant and consistent efficacy across a broad MS patient population, from children 10 years of age to older adults.  

Ninety percent of children with RMS treated with Ocrevus, who were 10-17 years old at trial entry, remained free of relapses over two years. Ocrevus selectively depleted target B cells with little to no effect on other immune cells, while preserving pre-existing immunity to common childhood vaccines in 81–100 percent of patients.

More than half of participants over 55 years old treated with Ocrevus showed no disability progression after two years, similarly to younger participants (55 percent), showing Ocrevus maintains its effect on progression as people age. 

Real-world data show progression was the leading reason for patients switching from ofatumumab to Ocrevus. A separate analysis of patients treated with Ocrevus or ofatumumab for one year show Ocrevus was associated with lower MRI lesion activity. 

Enspryng reduces risk of attack, linked to improved recovery 

Exploratory analyses of METEOROID trial data suggest in addition to significantly lowering the risk of relapse, Enspryng was linked to improved recovery and reduced disability progression, which is critical to prevent permanent damage to the optic nerves, spinal cord or brain in myelin oligodendrocyte glycoprotein antibody-associated disease. These findings reinforce Enspryng’s potential to become the first FDA-approved treatment for MOGAD, with a decision in the U.S. expected in January 2027. 

Patients treated with Enspryng achieved numerically superior recovery at 12 weeks post relapse versus placebo. Overall function was stable with Enspryng, compared to worsening with placebo, as measured with the EDSS at the end of the double-blind period or first relapse.

The findings were presented at the tenth ACTRIMS-ECTRIMS meeting, held in Toronto.





 

MS Focus Lending Library


Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more

Ocrelizumab study confirms benefits, safety profile

November 18, 2026

Treatment found to outperform interferon beta-1a in relapsing MS.
Learn more